Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome

Next Previous
Trial Profile

Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott-Aldrich Syndrome

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs WASp gene therapy (Primary)
  • Indications Wiskott-Aldrich syndrome
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Genethon

Most Recent Events

  • 19 Nov 2014 The primary endpoints have been changed from safety, immunological repose, engraftment outcomes, clinical outcomes to improvement in eczema, infection, bleeding, autoimmune disorders and reduction in number of hospitalization as per ClinicalTrials.gov.
  • 19 Nov 2014 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2017, according to ClinicalTrials.gov record.
  • 21 Apr 2014 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top